New MBC BioLabs Facility Coming Soon
We are happy to announce the opening of our new campus in San Carlos! The new site has 30,000 SF of lab and office space and over $1 million in research equipment to enable awesome for 40 of the most promising life-science startups in the Bay Area. 
Join us for hard-hat tours of our new San Carlos location on:
  • Thursday 1.23.20 1 pm @ 930 Brittan Ave, San Carlos
  • Tuesday 1.28.20 11 am @ 930 Brittan Ave, San Carlos
  • Tuesday 2.4.20 1 pm @ 930 Brittan Ave, San Carlos
  • Friday 2.14.20 2 pm @ 930 Brittan Ave, San Carlos
  • Wednesday 2.19.20 2 pm @ 930 Brittan Ave, San Carlos
  • Friday 2.28.20 2 pm @ 930 Brittan Ave, San Carlos
Please e-mail to save a spot in one of our regularly scheduled tours or to have us set up just the right time that works for you.
Creoptix Sponsors MBC BioLabs
MBC BioLabs is delighted to welcome Creoptix as our newest partner. They have placed a Creoptix WAVEdelta at MBC BioLabs San Carlos. The instrument is engineered around a proprietary waveguide interferometry technology, an its system delivers ultra-high sensitivity, fast kinetics, and robust microfluidics. By combining superior resolution in signal and time with crude-sample robustness normally only achieved with plate-based assays, the Creoptix WAVE system is revolutionizing the study of molecular interactions.
DNA Encoded Library Breakfast Seminar
January 16, 2020 from 9:00 to 11:00 AM
MBC BioLabs San Francisco
Please join us for an invitation-only breakfast to learn about DNA Encoded Libraries (DEL's) presented by Dr. Letian Kuai, Executive Director of DEL Technology and Strategy at WuXi.  DEL's enable rapid hit identification and optimization using affinity-based selections from libraries containing billions of DNA-encoded small molecules.

About WuXi AppTec:

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.

Phase Appropriate Method Validation
January 24, 2019 from 12:00 to 1:00 PM
MBC BioLabs San Carlos
Please join us for a lunch seminar presented by Aryo A. Nikopour, Nitto Avecia Pharma Services Senior Vice President of Analytical Strategy & Business Development. He will discuss about: Definition and Regulatory Requirements, Method Verification, Method Transfer and phase appropriate Method Validation, including stress studies and Method Validation Characteristics.
About Nitto Avecia Pharma Services:

Nitto Avecia Pharma Services has earned its reputation for providing outstanding analytical testing from small molecules to biologics for nearly 30 years. With the addition of a state-of-the-art manufacturing facility staffed by some of the industry's most experienced formulation scientists, Avecia Pharma guides its clients and expedites their time to market.


BigHat Biosciences is an early-stage Bay Area startup developing an AI-first experimental platform to radically reduce the difficulty of designing antibodies and other therapeutic proteins.

ExoPolymer is a biotechnology company focused on the production of unique, high performance biopolymers, or hydrocolloids, for the healthcare, personal care, food, pharmaceutical, and energy industries.  Our technology involves the development of a robust, safe, and economical biological fermentation platform for the production of proprietary, next-generation molecules that are substantially improved over currently available products.

Teon Therapeutics is a global biopharmaceutical company that discovers and develops small molecule drugs for cancer immunotherapy. Teon is committed to advance innovative therapeutic agents to address unmet global medical needs and improve the lives of patients.
To improve long-term outcomes for more patients with cancer, Teon Therapeutics believes more Immuno-Oncology based combinations may be required. With this core philosophy in mind, their first-in-class small molecule checkpoint inhibitors (A2B & UDT-1) are the backbone of their IO portfolio and offer differentiated combination therapies with their other potentially best in-class checkpoint inhibitors.